Brief: Poxel Announces Publication Of Imeglimin Clinical Study Results

Poxel SA

20/04/2020 17:20

April 20 (Reuters) - POXEL SA  POXEL.PA :
    * ANNOUNCES PUBLICATION OF IMEGLIMIN CLINICAL STUDY RESULTS
IN
CLINICAL PHARMACOKINETICS
    * TWO DRUG-DRUG INTERACTION STUDIES ASSESSED EFFECT OF
REPEATED
CO-ADMINISTRATION OF COMMONLY PRESCRIBED MEDICATIONS, METFORMIN
OR SITAGLIPTIN WITH IMEGLIMIN
    * REPEATED CO-ADMINISTRATION OF IMEGLIMIN WITH BOTH
MEDICATIONS
DID NOT RESULT IN CLINICALLY RELEVANT CHANGES IN DRUG EXPOSURE
LEVELS IN HEALTHY SUBJECTS
    * IMEGLIMIN WAS OBSERVED TO BE SAFE AND WELL TOLERATED IN
BOTH
STUDIES
    * PREPARATIONS ARE UNDERWAY FOR NEW DRUG APPLICATION
SUBMISSION
FOR IMEGLIMIN IN JAPAN, WHICH IS ANTICIPATED DURING Q3 OF 2020
WITH A TARGET LAUNCH IN 2021
    * COMPANY ANTICIPATES THAT THE COVID-19 PANDEMIC COULD HAVE
A
MATERIAL NEGATIVE IMPACT ON BUSINESS OPERATIONS
    * WORLDWIDE IMPACT OF COVID-19 MAY NOTABLY AFFECT COMPANY'S
INTERNAL ORGANIZATION AND EFFICIENCY
    * DELAYS IN SUPPLY OF DRUG SUBSTANCE OR DRUG PRODUCTS, AS
WELL AS
DELAYS LINKED TO RESPONSIVENESS OF REGULATORY AUTHORITIES COULD
OCCUR

Source text for Eikon:  ID:nBwS6YrPa 
Further company coverage:  POXEL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))